CureVac is a German biopharmaceutical company pioneering mRNA-based therapies and vaccines for infectious diseases, cancer immunotherapy, and rare diseases. Founded in 2000 in Tübingen, CureVac develops optimized mRNA candidates using proprietary platform technology including delivery formulations and manufacturing processes. The company operates research and development sites across Germany, Netherlands, Belgium, Switzerland, and the United States.
CureVac is publicly traded
IPO'd on August 14, 2020
This company is no longer available on our private secondary market. Shares can be traded publicly under CVAC.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2000
Employees
1,000-5,000
Total Funding
$810M
5 rounds
Last Private Valuation
$1.63B
July 20, 2020
Total raised $810M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Strategic (GSK / pre-IPO round)
Date
July 20, 2020
Amount
$285M
Valuation
$1.63B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| July 20, 2020 | Strategic (GSK / pre-IPO round) | $285M | $1.63B | GlaxoSmithKline |
| June 15, 2020 | Strategic / Government | $339M | $1.47B | German Federal Government |
| November 1, 2015 | Late stage (mega-round) | $110M | — | Baillie Gifford |
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.
Entry · Strategic / Government
$1.5B
Jun 2020
CureVac today
$1.6B
Jul 2020 · latest mark
CureVac multiple
1.1x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Ingmar Hoerr
Founder & CEO
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Moderna
US-based mRNA vaccine and therapeutic developer; leading mRNA market with 37.5% share as of 2024.
BioNTech
German mRNA vaccine and therapeutic platform company; now CureVac's parent company following December 2025 acquisition.
Arcturus Therapeutics
US-based biotech specializing in self-amplifying mRNA (saRNA) technology for infectious diseases and genetic disorders.
Yes, CureVac is publicly traded under the ticker symbol CVAC on the NASDAQ. The company went public in August 14, 2020.
CureVac trades under the ticker symbol CVAC on the NASDAQ. It began trading in August 14, 2020.
CureVac (CVAC on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker CVAC to place an order.
CureVac went public in August 14, 2020 via ipo, with an offering valuation of approximately $1.63B. CureVac was listed on NASDAQ under ticker CVAC following its August 2024 IPO at $16/share. In June 2025, BioNTech announced a strategic acquisition via public exchange offer, with the transaction closing on December 18, 2025, after 86.75% of shares were tendered. The exchange ratio was 0.05363 BioNTech ADSs per CureVac share. BioNTech expects to complete compulsory acquisition of remaining shares in January 2026, after which CureVac will be delisted from NASDAQ.
CureVac raised $810M across 5 disclosed funding rounds prior to its public listing.
CureVac was founded by Ingmar Hoerr in 2000.
CureVac is headquartered in Tübingen, Germany.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.